Research Article

LncRNA AWPPH promotes the growth of triple-negative breast cancer by up-regulating frizzled homolog 7 (FZD7)

Kainan Wang1,*, Xuelu Li2,*, Chen Song2 and Man Li2

1Department of Oncology, Dalian Medical University, Dalian City, Liaoning Province 116044, P.R. China; 2Department of Breast oncology, The Second Hospital of Dalian Medical University, Dalian City, Liaoning Province 116027, P.R. China

Correspondence: Man Li (tuoeh29@163.com)

Background: LncRNA AWPPH is a recently identified critical player in the development of several types of human malignancies, our study aimed to investigate the role of AWPPH in triple-negative breast cancer. Methods: In the present study, expression of AWPPH in tumor tissues and adjacent healthy tissues of patients with triple-negative breast cancer as well as in plasma of both patients and healthy people was detected by qRT-PCR. Application potentials of AWPPH in the diagnosis and prognosis of triple-negative breast cancer were evaluated by ROC curve analysis and survival curve analysis, respectively. AWPPH expression vectors and frizzled homolog 7 (FZD7) siRNAs were transfected into cells of human breast cancer cell lines. Expression of FZD7 was detected by Western blot, and cell proliferation was detected using CCK-8 kit. Results: We observed that AWPPH was significantly up-regulated in tumor tissues than in paired adjacent healthy tissues of patients. Plasma levels of AWPPH were higher in patients than in controls. AWPPH overexpression promoted cancer cell proliferation and up-regulated FZD7 expression. FZD7 siRNA silencing inhibited cancer cell proliferation but did not significantly affect AWPPH expression. Compared with cells with AWPPH overexpression alone, cells with both FZD7 siRNA silencing and AWPPH overexpression showed significantly reduced proliferation ability. Conclusions: We conclude that LncRNA AWPPH may promote the growth of triple-negative breast cancer by up-regulating FZD7.

Introduction

As one of the most common types of malignancy among females in the world breast cancer is responsible for 20% of deaths in women [1]. More and more studies have revealed that breast cancer is a heterogeneous disease that can be classified into different pathological subtypes with prognostic significance [2]. Categorization of breast cancer is mainly based on the expression of estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [3]. As a subtype of breast cancer, triple-negative breast cancer is characterized by the lack of ER and PR and the absence of HER2 overexpression [4]. Due to the extreme aggressive nature, low response rate to chemotherapy and lack of effective targeted therapies, prognosis of triple-negative breast cancer is generally poor [5].

The classic Wnt pathway plays pivotal roles in the development of different types of malignancies [6]. Wnt signaling is transduced through LRP5/lipoprotein receptor-related protein 6 (LRP6) co-receptor and Frizzled (FZD) family receptors to initiate the β-catenin signaling transduction [7]. As a critical player in Wnt pathway, frizzled homolog 7 (FZD7) has been proved to have pivotal functions in the regulation of cell proliferation in triple negative breast cancer [8]. It is known that Wnt pathway in some cases achieve its signaling transduction through the interactions with lncRNAs [9], which is a subgroup of non-coding

* These authors contributed equally to this work.

Received: 21 July 2018
Revised: 24 September 2018
Accepted: 28 September 2018
Accepted Manuscript Online: 17 October 2018
Version of Record published: 28 November 2018

© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
RNA and plays pivotal roles in cancer biology [10]. AWPPH is a newly identified oncogenic lncRNA in bladder cancer [11] and hepatocellular carcinoma [12]. In our study, we observed that AWPPH might promote tumor growth in triple negative breast cancer by up-regulating FZD7.

Materials and methods
Specimens
Tumor tissue and adjacent healthy tissue specimens of 68 patients with triple-negative breast cancer, and plasma specimens of both patients and 62 healthy controls were obtained from the specimen library of the Second Hospital of Dalian Medical University. The 68 patients were diagnosed through pathological examinations and treated in the Second Hospital of Dalian Medical University from January 2010 to January 2013. Inclusion criteria: (1) patients diagnosed with triple-negative breast cancer by pathological examinations; (2) patients who were diagnosed and treated for the first time; (3) patients completed the whole treatment procedure; (4) patients with complete treatment and follow-up data. Exclusion criteria: (1) patients with other malignancies and other types of breast cancer; (2) patients transferred to other hospitals during treatment; (3) patients died of other causes during follow-up. Age of 68 patients ranged from 22 to 61 years, with a mean age of 40.2 ± 6.1 years. Age of 62 healthy females ranged from 24 to 63 years, with a mean age of 41.7 ± 5.4 years. No significant differences in age, BMI and other clinical data were found between two groups. The present study has been approved by the ethics committee of the Second Hospital of Dalian Medical University. Written form informed consent was obtained from all participants and/or their families. All experiments on human materials were performed in accordance with the World Medical Association Declaration of Helsinki.

Real-time quantitative PCR
Total RNA extraction was performed using Trizol reagent (Invitrogen, U.S.A.) in strict accordance with manufacturer’s instruction. RNA with satisfactory quality was subjected to reverse transcription to synthesize cDNA. Systems of PCR reaction were prepared using SYBR Green PCR Master Mix (Thermo Fisher Scientific). Following primers were used in PCR reactions: 5′-CTGGATGGTCGCTGCTTTTTA-3′ (forward) and 5′- AGGGGGATGAGTCGTGATTT-3′ (reverse) for human lncRNA AWPPH; 5′-TTCTCGGACGATTGCACACC-3′ (forward) and 5′-GAACCAAGTGAGGAGAACAGACCGAC-3′ (reverse) for FZD7; 5′-GACCTCTATGACCAACACATTG3′ (forward) and 5′-AGTACGTGGTGAGACGAGA3′ (reverse) for β-actin. ABI PRISM 7500 sequence detection system (Applied Biosystems, Rockford, IL, U.S.A.) was used to perform all PCR reactions. PCR reaction cycles were: 95°C for 50 s, followed by 40 cycles of 95°C for 12 s and 60°C for 35 s. AWPPH expression was normalized to β-actin endogenous control using 2−ΔΔCt method.

Cell lines, cell culture and transfection
Human triple negative breast cancer cell lines MDA-MB-231 and BT-20 were from ATCC. Cells of two cell lines were cultured with ATCC-formulated Eagle’s Minimum Essential Medium (Catalog No. 30-2003) containing 10% final concentration fetal bovine serum. Human FZD7 siRNA (Catalog # AM16708) and Silencer® Negative Control #1 siRNA (Catalog # AM4611) were from Thermo Fisher Scientific. DNA fragments containing full-length AWPPH or FZD7 cDNA surrounded by two EcoRI cutting sites were amplified through PCR using cDNA derived from human cells. The fragments were inserted into EcoRI linearized pIRE2-EGFP vector (Clontech, Palo Alto, CA, U.S.A.) to construct AWPPH expression vector. Transfection was performed using Lipofectamine 2000 reagent (11668-019, Invitrogen, Carlsbad, U.S.A.) to transfet 10 mM vectors (10 nM) or 50 nM siRNAs into 5 × 105 cells. Transfection efficiency was checked by qRT-PCR before subsequent experiments.

Cell proliferation assay
Cell proliferation was detected by CCK-8 assay using a kit provided by Dojindo Molecular Technologies. Cell suspension with a cell density of 4 × 103 cells/ml was prepared using cells of two cell lines. Then 4 × 103 cells in 0.1 ml cell suspension was used to fill each well of a 96-well plate. Cells were cultured at 37°C with 5% CO2, and 10 μl of CCK-8 was added into each well at 24, 48, 72 and 96 h later. Cells were cultured for another 4 h and a microplate reader was used to measure OD values at 450 nm.

Western blot
RIPA solution (Thermo Fisher Scientific) was used for all protein extractions in strict accordance with manufacturer’s instructions. BCA method was used to measure protein concentration. SDS-PAGE gel (10%) electrophoresis was then
performed with 20 μg of protein per lane. Gel transfer was performed and PVDF membranes (Bio-Rad, U.S.A.) were incubated with skimmed milk (5%) for 2 h at room temperature for blocking. Membranes were then incubated with primary antibodies of FZD7 (rabbit anti human, ab64636, 1:1200; Abcam) and GAPDH (rabbit anti human, ab9485, 1:1200, Abcam) overnight at 4°C. Anti-rabbit IgG-HRP secondary antibody (1:1000, MBS435036, MyBioSource) was used to incubate with membranes the next day at room temperature for 2.5 h. ECL (Sigma-Aldrich, U.S.A.) was dropped onto membranes to develop signals, and ImageJ software was used to normalize FZD7 expression to GAPDH endogenous control.

**Statistical analysis**

Graphpad Prism 6 software was used in the present study. Expression and cell proliferation data were recorded as mean ± standard deviation. Student’s t test was used for comparisons between two groups and comparisons among multiple groups were performed by one-way analysis of variance followed by Tukey test. Correlation analysis between AWPPH expression and patients’ clinicopathological data was performed by Chi-square test. P<0.05 was considered to be statistically significant.

**Results**

**Comparison of AWPPH expression in tumor tissues and adjacent healthy tissues of triple-negative breast cancer patients**

Differential expression of an IncRNA in tumor tissues and paired normal tissues indicates the involvement of this IncRNA in diseases. In the present study, expression of AWPPH in tumor tissues and paired normal tissues of 68 patients with triple-negative breast cancer was detected. As shown Figure 1, significantly up-regulated AWPPH expression in tumor tissues than in paired normal tissues was found in 57 out of 68 patients, accounting for 83.5%. Therefore up-regulated expression of AWPPH is likely involved in the pathogenesis of triple-negative breast cancer.

**Comparison of plasma levels of AWPPH between patients and healthy controls and the potentials in disease diagnosis**

Changes in circulating substances in blood usually reflect certain pathological changes. In the present study, AWPPH was detected in plasma of both 68 patients and 64 healthy controls. As shown in Figure 2A, plasma levels of AWPPH were found to be significantly higher in patients than in healthy controls (P<0.05). Potentials of AWPPH in the diagnosis of triple-negative breast cancer were explored by ROC curve analysis. Results showed that the area under the curve was 0.8927, with standard error of 0.02637 and 95% confidence interval of 0.8510 to 0.9444 (P<0.0001).
Correlations between plasma levels of AWPPH expression and patients’ clinicopathological data
The 68 patients were divided into high and low expression groups according to the median plasma level of AWPPH, and correlation analysis between plasma levels of AWPPH and patients’ clinicopathological data was performed by Chi-square test. As shown in Table 1, plasma levels of AWPPH were not significantly correlated with age, BMI, smoking habit as well as existing of tumor distant metastasis. In contrast, a significant correlation was found between plasma levels of AWPPH and tumor size, indicating the potential involvement of AWPPH in tumor growth. In addition, plasma levels of AWPPH were also significantly correlated with TNM stages.

Potentials of AWPPH in the prognosis of triple-negative breast cancer
Data in Table 1 showed no significant correlations between plasma levels of AWPPH and distant metastasis, which is responsible for more than 90% cases of cancer-related deaths. Therefore, AWPPH is unlikely involved in tumor metastasis and survival data of all patients were analyzed together. Kaplan–Meier method was used to plot survival curves for high and low expression groups and survival curves were compared by log rank test. Results showed
that overall survival of patients in low AWPPH expression group was significantly better than that of patients in high expression group (Figure 3, $P<0.05$).

**Interactions between AWPPH and FZD7 in cells of human triple negative breast cancer cell lines**

Our data showed that AWPPH is probably involved in the growth of triple negative breast cancer. It has been reported that FZD7 plays critical roles in cell proliferation of this disease. Therefore, potential interactions between AWPPH on FZD7 were explored. As shown in Figure 4A, AWPPH overexpression significantly promoted the expression of FZD7 in cells of both MDA-MB-231 and BT-20 cell lines ($P<0.05$). In contrast, FZD7 overexpression showed no significant effects on AWPPH expression.

**Effects of AWPPH overexpression and FZD7 siRNA silencing on cell proliferation**

*In vitro* cell proliferation results showed that AWPPH overexpression significantly promoted, while FZD7 siRNA silencing significantly inhibited the proliferation of cells of MDA-MB-231 and BT-20 cell lines (Figure 5, $P<0.05$). In addition, compared with cells only transfected with AWPPH expression vectors, cells transfected with both AWPPH expression vectors and FZD7 siRNAs showed significantly reduced cell proliferation rate (Figure 5, $P<0.05$).

**Discussion**

The most important finding in our study is that AWPPH as a recently identified oncogenic IncRNA in bladder cancer [11] and hepatocellular carcinoma [12] may also play an oncogenic role in triple-negative breast cancer by promoting tumor cell proliferation. In addition, we also proved that the action of AWPPH in triple-negative breast cancer is probably achieved through the up-regulation of FZD7, which is a key player in Wnt signaling pathway.

Differential expression of a certain gene in lesion tissues and paired adjacent healthy tissues is a strong evidence of the involvement of this gene in human diseases. AWPPH was first identified as an oncogenic IncRNA overexpressed in hepatocellular carcinoma [12]. After that, overexpression of AWPPH has also been observed in bladder cancer tissues and cell lines [11]. In the present study, overexpression of AWPPH in tumor tissues than in adjacent healthy tissues was observed in most patients with triple-negative breast cancer, indicating that AWPPH may also be an oncogenic IncRNA in this disease. The fact that not all patients with triple-negative breast cancer show overexpression of AWPPH in cancer tissues indicates this molecular subtype of breast cancer may be also pathologically heterogeneous.

Pathological diagnosis is the gold standard for the diagnosis of most malignancies, while the invasive nature of this technique in some cases limits its application [13]. Changes in certain substances in blood with the development of human disease enable the use of circulating biomarkers in the diagnosis of human disease [14]. In our study, AWPPH was detected in the plasma of all patients with triple-negative breast cancer, and higher plasma levels of AWPPH were found in patients than in healthy controls. Further, ROC curve analysis also proved that up-regulation of AWPPH in plasma effectively distinguished triple-negative breast cancer patients from healthy controls. Besides that, plasma levels of AWPPH were not significantly correlated with age, BMI and smoking habits, which are verified prognostic
Figure 4. Interactions between AWPPH and FZD7 in cells of human triple negative breast cancer cell lines
This figure shows the effects of AWPPH overexpression on FZD7 expression (A) and the effects of FZD7 overexpression on AWPPH expression (B). *P<0.05.

Figure 5. Effects of AWPPH overexpression and FZD7 siRNA silencing on cell proliferation of triple-negative breast cancer cell lines MDA-MB-231 (A) and BT-20 (B).
*P<0.05.
factors for triple-negative breast cancer [15–17]. Those data suggest that AWPPH may participate in triple-negative breast cancer in a way independent from those factors.

Poor prognosis as main factor distinguished triple-negative breast cancer from other subtypes [18]. Tumor distant metastasis is the main cause of deaths in patients with malignancies [19]. In the present study, no significant correlations were found between plasma levels of AWPPH and the existing of distant tumor metastasis, while comparison of survival curves showed that up-regulated AWPPH expression is related to short survival time. Therefore, AWPPH may affect patients’ survival through factors other than tumor distant metastasis.

Correlation analysis indicates the involvement of AWPPH in tumor growth regulation, and in vitro cell proliferation analysis further confirmed this hypothesis. FZD7 as a critical player in Wnt pathway has pivotal functions in the regulation of cell proliferation in triple negative breast cancer [8]. In our study, we proved that AWPPH is likely an upstream positive regulator of FZD7 expression in the regulation of cell proliferation in triple-negative breast cancer. However, whether this regulatory role is direct or indirect is still unknown. It is worth to note that no significant changes in levels of FZD7 mRNA were observed after AWPPH overexpression. Therefore, AWPPH may affect FZD7 protein accumulation or degradation but not FZD7 gene transcription.

Conclusion

In conclusion, AWPPH is likely an oncogenic lncRNA with up-regulated expression pattern in triple-negative breast cancer. AWPPH may participate in triple-negative breast cancer by promoting tumor growth but not tumor metastasis through the up-regulation of FZD7.

Author Contribution

K.W. and X. L. designed and carried out the study. K.W., X.L. and C.S. participated in experiments and statistical analysis. K.W., X.L. and M.L. wrote the manuscript. M.L. revised the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This study was supported by the National Natural Science Foundation of China [81650018].

Abbreviations

ER, estrogen receptor; FZD7, frizzled homolog 7; HER2, human epidermal growth factor receptor 2; LRP6, lipoprotein receptor-related protein 6; PR, progesterone receptor.

References

1 DeSantis, C., Ma, J., Bryan, L. et al. (2014) Breast cancer statistics, 2013. CA Cancer J. Clin. 64, 52–62. https://doi.org/10.3322/caac.21203
2 Lv, M., Li, B., Li, Y. et al. (2011) Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac. J. Cancer Prev. 12, 2411–2417
3 Zubeda, S., Kaipa, P.R., Shaik, N.A. et al. (2013) Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac. J. Cancer Prev. 14, 2231–2235, https://doi.org/10.7314/APJCP.2013.14.4.2231
4 Podo, F., Buydens, L., Degani, H. et al. (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol. Oncol. 4, 209–229, https://doi.org/10.1016/j.molonc.2010.04.006
5 Brady-West, D.C. and McGrowder, D.A. (2011) Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac. J. Cancer Prev. 12, 2139–2143
6 ZD7, 18
7 Pinson, K.J., Brennan, J., Monks, S. et al. (2000) An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407, 535–538, https://doi.org/10.1038/35035124
8 Yang, L., Wu, X., Wang, Y. et al. (2011) FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30, 4437–4446, https://doi.org/10.1038/onc.2011.145
9 Cai, Y., He, J. and Zhang, D. (2015) Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco. Targets Ther. 8, 2657–2364
10 Schmitt, A.M. and Chang, HY. (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29, 452–463, https://doi.org/10.1016/j.ccell.2016.03.010
11 Zhu, F., Zhang, X., Yu, Q. et al. (2018) lncRNA AWPPH inhibits SMAD4 via EZH2 to regulate bladder cancer progression. J. Cell. Biochem. 119, 4496–4505, https://doi.org/10.1002/jcb.26556
12 Zhao, X., Liu, Y. and Yu, S. (2017) Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim. Biophys. Acta 1863, 1805–1816, https://doi.org/10.1016/j.bbapap.2017.04.014

© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
13 Mitchell, D.G., Snyder, B., Coakley, F. et al. (2006) Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J. Clin. Oncol. 24, 5687–5569, https://doi.org/10.1200/JCO.2006.07.4799

14 Heneghan, H.M., Miller, N., Lowery, A.J. et al. (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 251, 499–505, https://doi.org/10.1097/SLA.0b013e3181cc939f

15 Aapro, M. and Wildiers, H. (2012) Triple-negative breast cancer in the older population. Ann. Oncol. 23, vi52–vi55, https://doi.org/10.1093/annonc/mds189

16 Barba, M., Vici, P., Pizzuti, L. et al. (2017) Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer 17, 101, https://doi.org/10.1186/s12885-016-3045-z

17 Baglia, M.L., Cook, L.S., Tang, M.T. et al. (2018) Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. Int. J. Cancer 143, 1849–1857

18 Kong, W., He, L., Richards, E.J. et al. (2014) Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33, 679–689, https://doi.org/10.1038/onc.2012.636

19 Ward, E.M., DeSantis, C.E., Lin, C.C. et al. (2015) Cancer statistics: breast cancer in situ. CA Cancer J. Clin. 65, 481–495, https://doi.org/10.3322/caac.21321